• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估健康相关生活质量试验的效用:临床医生视角下的两个慢性阻塞性肺疾病实例

Assessing the usefulness of health-related quality-of-life trials: a clinician's perspective using two COPD examples.

作者信息

Phung Olivia J, White C Michael, Baker William L, Coleman Craig I

机构信息

University of Connecticut/Hartford Hospital Evidence-Based Practice Center, Hartford, CT 06102, USA.

出版信息

Ann Pharmacother. 2009 Sep;43(9):1496-505. doi: 10.1345/aph.1M211. Epub 2009 Aug 18.

DOI:10.1345/aph.1M211
PMID:19690221
Abstract

OBJECTIVE

To empower clinicians to discern when health-related quality-of-life (HRQoL) evidence from a single trial, or from constituent trials within a systematic review or meta-analysis, is compelling enough to alter clinical practice.

DATA SOURCES

To determine the criteria that would be most useful in assessing the quality of HRQoL data, recommendation statements or consensus guidelines that offer guidance to those conducting HRQoL trials were located through a MEDLINE search (1950-April 2009) using the search terms health-related quality of life and recommendations or guidelines.

STUDY SELECTION AND DATA EXTRACTION

Recommendation statements or consensus guidelines that offer guidance to investigators conducting HRQoL trials were evaluated to determine what criteria would be the most useful in assessing the quality of HRQoL data.

DATA SYNTHESIS

We discuss how quality of HRQoL data may be assessed by evaluating the following broad questions: (1) Is the HRQoL analysis hypothesis-driven? (2) How is HRQoL being measured? (3) Are the HRQoL data being collected adequately and analyzed correctly? and (4) To what extent do investigators discuss the results of HRQoL analyses? Using select examples from the literature on chronic obstructive pulmonary disease, we applied the 4 broad questions in the assessment of their quality. Also, the use of scoring systems for quality rating for HRQoL data is discussed and applied to the example cases.

CONCLUSIONS

HRQoL data are an important outcome because they capture treatment impact on physical, social, and psychological well-being. Assessing the quality and usefulness of HRQoL data requires an understanding of the advantages, limitations, and caveats of their use. Because of the potential lack of quality in HRQoL outcomes, clinicians should thoroughly assess the validity and usefulness of the evaluation. Tools are available to aid clinicians and decision-makers in the assessment of HRQoL outcomes, but additional research needs to be conducted on the topic of quality assessment of HRQoL studies to improve the usefulness of these evaluations to clinicians.

摘要

目的

使临床医生能够判断来自单项试验、或系统评价或荟萃分析中的组成试验的健康相关生活质量(HRQoL)证据是否足以令人信服,从而改变临床实践。

数据来源

为确定在评估HRQoL数据质量时最有用的标准,通过使用检索词“健康相关生活质量”和“推荐意见或指南”在MEDLINE数据库(1950年至2009年4月)中进行检索,查找为开展HRQoL试验的人员提供指导的推荐声明或共识指南。

研究选择与数据提取

对为开展HRQoL试验的研究者提供指导的推荐声明或共识指南进行评估,以确定在评估HRQoL数据质量时哪些标准最为有用。

数据综合

我们讨论如何通过评估以下几个宽泛的问题来评估HRQoL数据的质量:(1)HRQoL分析是否以假设为驱动?(2)HRQoL是如何测量的?(3)HRQoL数据的收集是否充分且分析是否正确?以及(4)研究者在多大程度上讨论了HRQoL分析的结果?我们使用慢性阻塞性肺疾病文献中的精选实例,将这4个宽泛的问题应用于其质量评估。此外,还讨论了HRQoL数据质量评分系统的使用,并将其应用于实例。

结论

HRQoL数据是一项重要的结果,因为它们反映了治疗对身体、社会和心理健康的影响。评估HRQoL数据的质量和实用性需要了解其使用的优点、局限性和注意事项。由于HRQoL结果可能存在质量问题,临床医生应全面评估评估的有效性和实用性。有工具可帮助临床医生和决策者评估HRQoL结果,但关于HRQoL研究质量评估这一主题还需要开展更多研究,以提高这些评估对临床医生的实用性。

相似文献

1
Assessing the usefulness of health-related quality-of-life trials: a clinician's perspective using two COPD examples.评估健康相关生活质量试验的效用:临床医生视角下的两个慢性阻塞性肺疾病实例
Ann Pharmacother. 2009 Sep;43(9):1496-505. doi: 10.1345/aph.1M211. Epub 2009 Aug 18.
2
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
3
Eliciting adverse effects data from participants in clinical trials.从临床试验参与者中获取不良反应数据。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.
4
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.评估慢性阻塞性肺疾病干预措施的比较效果:面向临床医生的网状Meta分析教程
Respir Res. 2024 Dec 21;25(1):438. doi: 10.1186/s12931-024-03056-x.
5
Self-management interventions for people with chronic obstructive pulmonary disease.针对慢性阻塞性肺疾病患者的自我管理干预措施。
Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD002990. doi: 10.1002/14651858.CD002990.pub4.
6
Review of guidelines for good practice in decision-analytic modelling in health technology assessment.卫生技术评估中决策分析模型良好实践指南综述。
Health Technol Assess. 2004 Sep;8(36):iii-iv, ix-xi, 1-158. doi: 10.3310/hta8360.
7
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
8
Shared decision-making for people with asthma.哮喘患者的共同决策
Cochrane Database Syst Rev. 2017 Oct 3;10(10):CD012330. doi: 10.1002/14651858.CD012330.pub2.
9
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
10
Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.慢性阻塞性肺疾病患者自我管理干预措施(包括针对病情加重的行动计划)与常规护理的比较。
Cochrane Database Syst Rev. 2017 Aug 4;8(8):CD011682. doi: 10.1002/14651858.CD011682.pub2.

引用本文的文献

1
The influence of psychological variables on health-related quality of life among HIV-positive individuals with a history of intravenous drug use.心理变量对有静脉注射吸毒史的 HIV 阳性个体健康相关生活质量的影响。
J Psychoactive Drugs. 2013 Sep-Oct;45(4):304-12. doi: 10.1080/02791072.2013.825030.